Evidence Hub

Screening strategy using a filamentous fungus model to repurpose drugs for mitochondrial complex I deficiencies

Sellem CH, Bounaix N, Logerais M, Renaud A, d'Elia MA, Richard J, Almyre C, Becker G et al.

Life sciences, 2026

1 citation

Abstract

AIM

This study aimed to repurpose FDA-approved drugs for the treatment of mitochondrial complex I diseases.

MATERIALS AND METHODS

The NUO-51 protein of the filamentous fungus Podospora anserina is the homolog of the human key catalytic subunit of complex I, NDUFV1. By introducing a pathogenic mutation into P. anserina NUO-51 we created a novel model of complex I deficiency targeting the NDUFV1 subunit. The thermosensitive phenotype of the fungal mutant enabled us to screen a library of nearly one thousand FDA-approved molecules. We have implemented various techniques such as growth analysis, oxygen consumption measurements, complex I activity assays and western blotting on Podospora, Caenorhabditis elegans and human on equivalent NDUFV1 mutant models, treated or untreated with the most effective drugs found during the screen.

KEY FINDINGS

We isolated a series of compounds able to rescue the growth defect of the Podospora nuo-51 mutant, including ligands of serotonin receptors or transporters. Among the selected drugs, alverine citrate (ALV) and dapoxetine hydrochloride (DAP) emerged as the most active drugs. Both drugs enhanced respiration and complex I activity, not only in the Podospora mutant, but also in Caenorhabditis elegans worms deficient for the NDUFV1 ortholog and in fibroblast from patient carrying NDUFV1 mutations.

SIGNIFICANCE

Together, our work demonstrates the usefulness of Podospora anserina as fungal model for identifying promising therapeutic candidates for…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free